							<u> </u>	HEEI	<u> </u>	
INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 39754-0672A US			SERIAL NO.09/847,208			
S			2 \		ANT: Andrew Saxon	et al				
	PTO-1449 DEC	20	200 931			<del></del>	<del></del>			
100				FILING DATE: 5/1/2001			GROUP: 1644			
	, Edit	REW	MESE U.S.	PATE	NT DOCUMENTS					
EXAMINER'S INITIALS			DATE		NAME		CLASS SUBCLASS FILING D		DATE	
				ļ			_		<u> </u>	
		_						-		
					<del></del>			L		
	т			GN PA	TENT DOCUMENTS	1 00 : 55	CLIDG! +CC	TDANC	LATION	
EXAMINER'S INITIALS	PATENT NO.	DATE			COUNTRY	CLASS	SUBCLASS	YES	NO	
		-	206		wo ·			<u></u>		
PH	96/22024		25.07.96			<del>  \</del>		<del>-</del>	一	
	99/02709	21.01.99			wo	<del>                                     </del>	X		H	
_\/			21.01.99		wo					
<u> </u>	99/02711 21.0		1.01.99		wo			(i		
·					Author, Title, Date, P					
PH	Antibody Forma	Borel et al., "Oligonucleotide Linked to Human Gammaglobulin Specifically Diminishes Anti-DNA Antibody Formation in Cultured Lymphoid Cells from Patients with Systemic Lupus Erythematosus" J. Clin. Invest., vol. 82, pp. 1901-1907 (1988).								
РН	Borel et al., "A Tolerogens" J.	Borel et al., "A Novel Technique to Link either Proteins or Peptides to Gammaglobulin to Construct Tolerogens" J. of Immun. Methods, vol. 126, pp. 159-168 (1990).								
						•				
			· · · · · · · · · · · · · · · · · · ·							
<u> </u>	_									
					· · · · · · · · · · · · · · · · · · ·					
			· ·							
	+					<u></u>				
	<del>-  </del>									
<u></u>	•									
						·	· · · · · · · · · · · · · · · · · · ·			
		<del>.</del>					<del></del> _			
•	/Ph		<del></del>			03/05	/2007	<u> </u>		
EXAMINER	/Phuong H	råuu\		DAT	E CONSIDERED	55,05				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.